One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to Tesamorelin in 中国. US research-market identity with a separate FDA-licensed medicine record.

Current source route

Tesamorelin in 中国

Direct answer / 中国

Can you buy Tesamorelin in 中国?

US research-market identity with a separate FDA-licensed medicine record

This record resolves seller-labelled 10 mg tesamorelin research listings. EGRIFTA WR is a separate FDA-licensed prescription product with a specific application, 11.6 mg presentation, indication, label, and regulated supply chain. The research listings do not inherit that approval.

  1. 01
    Resolve the nameResearch price board
  2. 02
    Check 中国Research price board
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordUS research-market identity with a separate FDA-licensed medicine record

What Tesamorelin resolves to

This record resolves seller-labelled 10 mg tesamorelin research listings. EGRIFTA WR is a separate FDA-licensed prescription product with a specific application, 11.6 mg presentation, indication, label, and regulated supply chain. The research listings do not inherit that approval.

Evidence lane
Research price board
Current record
4 of 5 rows in stock
Checked
Jul 23, 2026
EgriftaTH9507
Destination record必须按具体产品与经营主体分别核验

What 中国 still has to prove

本指南面向在中国搜索肽类、多肽药物、减重药物和研究材料的用户,提供以国家药品监督管理局药品数据和国家企业信用信息公示系统为起点的核验路径。它将具体药品批准、批准持有人、剂型规格、企业登记和网络供应声明分开处理,避免把名称相同、中文页面、人民币价格或境内发货承诺误当成产品已经获批或卖方已经验证的证据。

Comparison mode
人民币 / 药品批准与企业登记记录
Price coverage
暂无符合发布标准的中国卖方价格表
Guide updated
2026年7月18日
Evidence coverageRouting records only

No compound-specific official record is attached to this exact pairing yet. That is an evidence gap, not proof of approval, prohibition, availability, or absence. Use the country guide and official product and seller routes to verify the exact offer.

Open the full country check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail